251 related articles for article (PubMed ID: 29297494)
1. Neuroendocrine tumors of the prostate.
Fine SW
Mod Pathol; 2018 Jan; 31(S1):S122-132. PubMed ID: 29297494
[TBL] [Abstract][Full Text] [Related]
2. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
Epstein JI; Amin MB; Beltran H; Lotan TL; Mosquera JM; Reuter VE; Robinson BD; Troncoso P; Rubin MA
Am J Surg Pathol; 2014 Jun; 38(6):756-67. PubMed ID: 24705311
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
4. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
[No Abstract] [Full Text] [Related]
5. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
[TBL] [Abstract][Full Text] [Related]
6. Reprint of: de novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
[TBL] [Abstract][Full Text] [Related]
7. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
8. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
9. De novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2022 Sep; 127():112-122. PubMed ID: 35810832
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects.
di Sant'Agnese PA
Urology; 1998 May; 51(5A Suppl):121-4. PubMed ID: 9610566
[TBL] [Abstract][Full Text] [Related]
14. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
15. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.
Priemer DS; Montironi R; Wang L; Williamson SR; Lopez-Beltran A; Cheng L
Endocr Pathol; 2016 Jun; 27(2):123-35. PubMed ID: 26885643
[TBL] [Abstract][Full Text] [Related]
17. [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].
Bonkhoff H; Fixemer T
Pathologe; 2005 Nov; 26(6):453-60. PubMed ID: 16195860
[TBL] [Abstract][Full Text] [Related]
18. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
19. Primary Prostatic Carcinoma With De Novo Diffuse Neuroendocrine Differentiation.
Galea LA; Mow C; Fine SW; Manohar P
Int J Surg Pathol; 2022 Apr; 30(2):232-236. PubMed ID: 34338584
[TBL] [Abstract][Full Text] [Related]
20. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
